The “2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations” (DOI: 10.1159/000486145) highlights the importance of IOP management with intravitreal injections:

“In most cases, the IOP elevations are either transient or easy to control by topical treatments. However, both short- and long-term IOP elevations are undesirable, especially in patients with prior glaucomatous damage. Therefore, the injecting ophthalmologist should always be aware of pre-existing ocular hypertension or glaucoma, and monitor IOP carefully.”

What is the point of view of glaucoma specialists on this issue?  In the following videos, three of the top opinion leaders in glaucoma share their experience with you and provide useful advice.

For the pdf of Euretina recommendations click here

E Randy Craven, MD


Gabor Hollò, MD


Frances Meier-Gibbons, MD